OncoZenge participates in MASCC cancer care conference June 27-29

Stockholm, Sweden – June 4 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces its participation in the 2024 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Lille, France on June 27-29, 2024.

The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. Consistent with MASCC’s purpose the conference focuses on the latest advancements and best practices in cancer supportive care.

The conference will provide a unique opportunity for OncoZenge to meet Key Opinion Leaders from Europe and around the world, sharing plans for the continued development and anticipated market introduction of BupiZenge™. BupiZenge™ promises to offer patients suffering from cancer-induced oral pains significant pain relief and quality of life benefits compared to today’s inadequate standard of care.

Governments and healthcare has an increasing focus on early detection and treatment of cancer, as well as quality of life, as evidenced by the EU Mission on Cancer where one of the four primary objectives aim to significantly improve patients Quality of Life during treatment. Governments and healthcare also strive to limit the use of systemic opioids to reduce the burden on patients and society from the ‘opioid crisis’.

The overall theme of the conference is to ‘Empower People Impacted by Cancer and Living with Toxicities’. The program will cover:

-        Home Care and Extending Supportive Care at Home or Closer to Home
-        Management of Emerging Toxicities
-        Innovative Implementation of Supportive Care in Cancer
-        Quality Improvement in Supportive Care

The Chair of the Mucositis Study Group at MASCC, Dr. Paolo Bossi, a Medical Oncologist and Associate Professor at the Humanitas Cancer Center in Milan, Italy, also serves as a member of the OncoZenge Advisory Board.

“We are excited to particpate in the 2024 MASCC annual meeting and to connect with leading experts in our field,” said Stian Kildal, CEO at OncoZenge. “Our planning for the phase 3 clinical trial together with a partner is progressing well, and we are therefore able to share preliminary plans for the final development and market introduction of BupiZenge. As we take important steps towards the market, creating awareness, gathering support and feedback from Key Opinion Leaders becomes all the more important on our journey to offer cancer patients effective pain control. At the same time, future licensees will benefit from local references in the medical profession as they evaluate the commercial opportunity to partner with OncoZenge.”